NEW YORK – After kicking off last month's J.P. Morgan Healthcare Conference in San Francisco, Celgene Corp. sounded the starter pistol for this year's BIO CEO & Investor Conference, with CEO Bob Hugin taking the seat in the meeting's first fireside chat Monday morning at the Waldorf-Astoria hotel. Read More
Avalon Ventures scored again for the third time in recent weeks, as antibiotics-focused RQx Pharmaceuticals Inc. is expected to make public today a deal worth as much as $111 million with Genentech, part of Roche AG. Read More
The weekend "snowmageddon" deterred few from attending this year's BIO CEO & Investor Conference – a BIO rep, in fact, said only one speaker had to cancel – and attendees made their way to the Waldorf-Astoria hotel on Park Avenue through slush-filled sidewalks on a rainy Monday morning. Read More
With sequestration set to trigger in less than three weeks, the FDA, National Institutes of Health (NIH) and other federal agencies are preparing for the worst while still hoping to be spared. Read More
At least with mouse models of inflammation, there's apparently no concern about what conclusions are legitimate to draw from a correlation between those models and inflammation in humans. Read More
LONDON – e-Therapeutics plc is copper-bottoming its future, raising £40 million (US$62.66) in a share issue which, added to existing resources of £8 million, will fund the network pharmacology specialist until 2017. Read More
• AMRI, of Albany, N.Y., signed a license agreement with Chai Therapeutics LLC, an affiliate of Bessor Pharma LLC, of Framingham, Mass., to develop its tubulin inhibitor, ALB109564, which is in Phase I testing. Read More
• Catabasis Pharmaceuticals Inc., of Cambridge, Mass., said a three-part series of Phase I studies showed that CAT-1004, a SMART Linker conjugate of docosahexaenoic acid (DHA) and salicylate created using the company's technology, was safe and well tolerated. Data also showed that the conjugated compound was absorbed following oral administration and metabolized to its active components intracellularly, providing proof of concept for the SMART Linker platform. Read More
• Perrigo Co., of Allegan, Mich., completed the acquisition of Rosemont Pharmaceuticals Ltd., of Leeds, UK, for approximately £180 million ($283 million) in cash. Rosemont, a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations, had 2012 net sales of approximately £40 million. Read More
